Back to top
more

Albireo Pharma, Inc. (ALBO)

(Delayed Data from NSDQ)

$36.36 USD

36.36
39,062

+1.29 (3.68%)

Updated May 3, 2019 04:00 PM ET

After-Market: $36.19 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Aeglea Biotherapeutics (AGLE) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Aeglea (AGLE) delivered earnings and revenue surprises of 10% and 1.18%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Ginkgo Bioworks Holdings, Inc. (DNA) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Ginkgo Bioworks Holdings, Inc. (DNA) delivered earnings and revenue surprises of 86.67% and 16.44%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Mirum Pharmaceuticals, Inc. (MIRM) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Mirum Pharmaceuticals, Inc. (MIRM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Is Albireo Pharma (ALBO) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Albireo Pharma (ALBO) and Lantheus Holdings (LNTH) have performed compared to their sector so far this year.

Alnylam Pharmaceuticals (ALNY) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Alnylam (ALNY) delivered earnings and revenue surprises of 21.13% and 9.37%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Deciphera Pharmaceuticals, Inc. (DCPH) delivered earnings and revenue surprises of -5.26% and 2.59%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Albireo Pharma (ALBO) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Albireo Pharma (ALBO) delivered earnings and revenue surprises of -1.61% and 1.58%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Celldex Therapeutics (CLDX) Q3 Earnings Expected to Decline

by Zacks Equity Research

Celldex (CLDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Albireo Pharma (ALBO) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Albireo Pharma (ALBO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Albireo (ALBO) Up on Results From Alagille Syndrome Study

by Zacks Equity Research

Albireo Pharma (ALBO) reports positive top-line data from a late-stage study evaluating Bylvay in Alagille syndrome. The study meets the primary and key secondary endpoint Stock up.

Albireo Pharma (ALBO) Soars 14.4%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Albireo Pharma (ALBO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Albireo Pharma (ALBO) Stock Jumps 11%: Will It Continue to Soar?

by Zacks Equity Research

Albireo Pharma (ALBO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Albireo Pharma (ALBO) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Albireo Pharma (ALBO) delivered earnings and revenue surprises of -29.11% and 12.89%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Is Albireo Pharma (ALBO) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Albireo Pharma (ALBO) and Arcutis Biotherapeutics, Inc. (ARQT) have performed compared to their sector so far this year.

Absci Corporation (ABSI) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Absci Corporation (ABSI) delivered earnings and revenue surprises of 0% and 38.53%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

NeoGenomics (NEO) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

NeoGenomics (NEO) delivered earnings and revenue surprises of 27.27% and 0.86%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Novavax (NVAX) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Novavax (NVAX) delivered earnings and revenue surprises of -218.51% and 82.16%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Has Albireo Pharma (ALBO) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Albireo Pharma (ALBO) and GT Biopharma, Inc. (GTBP) have performed compared to their sector so far this year.

Albireo Pharma (ALBO) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Albireo Pharma (ALBO) delivered earnings and revenue surprises of -8.42% and 12.62%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Viridian Therapeutics, Inc. (VRDN) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Viridian Therapeutics, Inc. (VRDN) delivered earnings and revenue surprises of -6.52% and 66.77%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Exelixis (EXEL) Tops Q1 Earnings Estimates

by Zacks Equity Research

Exelixis (EXEL) delivered earnings and revenue surprises of 50% and 6.02%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Albireo Pharma (ALBO) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Albireo Pharma (ALBO) delivered earnings and revenue surprises of 55.12% and 164.33%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Is a Surprise Coming for Albireo Pharma (ALBO) This Earnings Season?

by Zacks Equity Research

Albireo Pharma (ALBO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Intellia Therapeutics, Inc. (NTLA) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Intellia Therapeutics, Inc. (NTLA) delivered earnings and revenue surprises of -19.78% and 33.35%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

The Zacks Analyst Blog Highlights Teladoc Health, Albireo Pharma and The Joint Corp

by Zacks Equity Research

Teladoc Health, Albireo Pharma and The Joint Corp are included in this blog.